Ribonucleic Acid News and Research

RSS

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

A fascinating new preprint research paper posted to the bioRxiv* server discusses impressively high neutralizing responses elicited with a single dose of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine formulation, which could help turn the tide of the current pandemic if validated.

6 Apr 2021

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

A new study describes the identification of new compounds from a library, with inhibitory activity against several coronaviruses. This study shows the utility of this method, besides identifying compounds that not only inhibit viral shedding in SARS-CoV-2 cultures, but have an immunomodulatory effect that may be useful in mitigating the damaging cytokine storm typical of severe or critical COVID-19.

2 Apr 2021

Discovery of cryptic pocket in SARS-CoV-2 may lead to pan-coronavirus therapies

A new research paper published in the Biophysical Journal describes a novel binding pocket used by a viral non-structural protein (nsp) to form an activated complex with its partner nsp. In so doing, it may have revealed a common target that may be useful in the development of a broad-spectrum antiviral drug against all coronaviruses.

1 Apr 2021

Study shows how viral distribution of SARS-CoV-2 in the human body relates to tissue damage

Researchers have mapped the distribution of SARS-CoV-2, the virus that causes COVID-19, in deceased patients with the disease, and shed new light on how viral load relates to tissue damage.

31 Mar 2021

mRNA COVID-19 vaccines are highly effective among front liners, CDC study shows

The study, published in CDC's Morbidity and Mortality Weekly Report (MMWR), highlights the efficacy of mRNA vaccines in protecting against SARS-CoV-2 infection.

30 Mar 2021

Study finds rapid increase in IgG and IgA antibody levels following COVID-19 mRNA vaccination

A new study describes the kinetics of the antibody response to the earliest approved vaccines against COVID-19, which were developed on an mRNA platform.

30 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

Could dry swabs provide cheaper, safer and faster material for SARS-CoV-2 testing?

A new study deals with the feasibility of using dry swab samples to isolate the virus, as compared to wet swabs, to reduce costs while improving safety.

25 Mar 2021

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

A new study adds to the sum of knowledge about SARS-CoV-2, with respect to its natural and biologically significant mutations, using computational modeling of the virus-receptor interactions. Understanding how viral mutations affect the virus-host interactions is crucial for shaping proper strategies to control the virus.

24 Mar 2021

Clofazimine inhibits coronaviruses including SARS-CoV-2, study finds

Researchers at the University of Hong Kong found that Clofazimine, a lipophilic antimicrobial riminophenazine dye used in combination with agents like rifampicin and dapsone to treat leprosy, inhibits coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease.

21 Mar 2021

SARS-CoV-2 spike stimulates hyperinflammation via Toll-like receptor 2

A new study, released on the bioRxiv* preprint server, describes the mechanism of inflammation in severe COVID-19, besides revealing a potential new therapeutic target to modulate the severity of COVID-19.

19 Mar 2021

Testing for mRNA-1283, Moderna's next generation COVID-19 vaccine commences

As vaccine efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease, roll out in various countries, Moderna ups the game by testing its next-generation COVID-19 vaccine.

16 Mar 2021

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

In a study published in the journal Drugs, a researcher tackled the approval of Pfizer-BioNTech’s COVID-19 vaccine, which has now been used in many countries.

12 Mar 2021

TraCK study says schoolchildren unlikely to transmit SARS-CoV-2

An interesting new preprint research paper posted to the medRxiv* server reports there is little evidence to suggest the rapid transmission of the virus among school children while attending school.

10 Mar 2021

Danish study on the efficacy of Pfizer/BioNTech SARS-CoV-2 vaccine after first and second dose

As the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, many countries have rolled out vaccines against the virus. In an encouraging preprint research paper posted to the medRxiv* server, scientists report on the vaccine efficacy in the Danish vaccination program.

10 Mar 2021

mRNA COVID-19 vaccines show high efficacy in pregnancy and lactation

A reassuring study reports the immunogenicity and lack of reactogenicity of the coronavirus disease 2019 (COVID-19) vaccine when given to this group of subjects. This will contribute to the sum of knowledge about the implications of vaccination in this high-risk cohort.

10 Mar 2021

SARS-CoV-2 variants rapidly arise in non-human hosts, potential risk for human reinfection

The study, published on the preprint server bioRxiv*, highlights the need to study viral evolution and pathogenesis in human and animal hosts. This could help prevent future outbreaks that may mimic the magnitude of the current COVID-19 pandemic.

9 Mar 2021

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

A new study, released as a preprint on the bioRxiv* server, reports an optimized coronavirus disease 2019 (COVID-19) vaccine candidate, which, claim the researchers, may be less likely to produce reactions like fevers. It may also have increased protective potential against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes COVID-19.

9 Mar 2021

Proteomics shows SARS-CoV-2 NSP7 and NSP8 forms stable dimeric unit

A new preprint, released on the bioRxiv* preprint server, describes the structure of part of the dynamic protein-RNA complex known as the replication-transcription complex (RTC), which is crucial in the replication of the large ribonucleic acid (RNA) genome of this virus.

9 Mar 2021

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Researchers at the Pitié Salpêtrière Hospital, Department of Virology, Paris, France determined that in BNT162b2-vaccinated participants who received two doses, their sera harbored at least a neutralizing titer against the three SARS-CoV-2 variants.

8 Mar 2021

Ribonucleic Acid News and Research

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

Discovery of cryptic pocket in SARS-CoV-2 may lead to pan-coronavirus therapies

Study shows how viral distribution of SARS-CoV-2 in the human body relates to tissue damage

mRNA COVID-19 vaccines are highly effective among front liners, CDC study shows

Study finds rapid increase in IgG and IgA antibody levels following COVID-19 mRNA vaccination

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

Could dry swabs provide cheaper, safer and faster material for SARS-CoV-2 testing?

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

Clofazimine inhibits coronaviruses including SARS-CoV-2, study finds

SARS-CoV-2 spike stimulates hyperinflammation via Toll-like receptor 2

Testing for mRNA-1283, Moderna's next generation COVID-19 vaccine commences

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

TraCK study says schoolchildren unlikely to transmit SARS-CoV-2

Danish study on the efficacy of Pfizer/BioNTech SARS-CoV-2 vaccine after first and second dose

mRNA COVID-19 vaccines show high efficacy in pregnancy and lactation

SARS-CoV-2 variants rapidly arise in non-human hosts, potential risk for human reinfection

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

Proteomics shows SARS-CoV-2 NSP7 and NSP8 forms stable dimeric unit

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News